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Purpose: The object of this study was to examine biopsies of repair tissue, 
from cartilage defects in patients treated with autologous chondrocyte 
implantation (ACI), to determine if lubricin (SZP or PRG4) is produced in the 
surface zone, as occurs in normal articular cartilage. 
Methods and Materials: Biopsies of the repair site were obtained from 9 
patients 8-20 months (mean 12.5 months) post-treatment (patients were 
aged 19-54, mean 36.5 years, at treatment). Two of the 9 patients were 
treated with chondrogide® in place of periosteum used for the other 7. 
Cryosections of biopsies were immunostained with a rabbit polyclonal 
antibody raised against human lubricin (G35) and studied with standard 
histology for morphology. 
Results: There was immunopositivity for lubricin in the bone underlying 
the repair tissue in most of the samples (8/9). All but 1 sample also had 
staining for lubricin in the cartilage; in 5 out of 9 it was in the cells and the 
matrix within the surface zone (including 1 of the patients treated with 
chondrogide®). In addition, there was some immunopositivity in small 
areas within the cartilage in 4/9 samples, usually towards the deep zone. 
Conclusions: The surface staining pattern for lubricin, typical of normal 
articular cartilage, appears to be recreated in >50% of biopsies of repair 
tissue from patients undergoing ACI treatment of cartilage defects, within 
12 months of treatment. It is likely that production of this molecule at the 
surface of the repair tissue would improve the functioning of the tissue and 
lowering of frictional forces arising during normal joint articulation. 
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Purpose: The current study investigated the relationship between 
GAG density and the compressive modulus for tissue-engineered 
constructs produced by goat articular chondrocytes in type II collagen 
scaffolds with increasing cross-link density, as a basis for employing 
constructs of selected maturity (e.g., 25, 50, or 75% normal GAG 
content) for cartilage repair. 
Methods and Materials: Porous scaffolds (8mm diam. by 3mm 
thick) were fabricated from porcine type II collagen (Geistlich 
Biomaterials, Wolhusen, Switzerland) by freeze-drying, followed by 
dehydrothermal treatment and carbodiimide cross-linking. Passage 
2 caprine articular chondrocytes isolated from 3 animals were grown 
in 6 cross-link groups for 2, 3, 4, 5, 6, and 9 weeks. The equilibrium 
NPEVMVTGSPNVODPO¾OFEDPNQSFTTJPOUFTUJOHXBTDPSSFMBUFEXJUI
GAG content (n=6). 
Results: There was an increase in GAG content with decreasing 
cross-link density and increasing time in culture. Histological 
BOBMZTJT WFSJ¾FE B DIPOESPHFOJD QIFOPUZQF BOE SFWFBMFE WBSJPVT
amounts of type II collagen-containing cartilage. The correlation 
between modulus and GAG density varied among groups, with the 
IJHIFTUMJOFBSDPFG¾DJFOUPGEFUFSNJOBUJPOCFJOH5IFNPEVMVT
GAG relationship for the constructs was different from that of normal 
tissue. One group with GAG density of 15±10µg/mm3 (mean±SD), 
which was 55% of that of normal tissue, averaged a compressive 
modulus of 33±16kPa, ~10% of caprine articular cartilage tested in 
this study. 
Conclusions: The GAG density and modulus of tissue-engineered 
constructs can be controlled by the degree of cross-linking of type II 
collagen scaffolds and time in culture. Modulus increases with GAG 
density, but following a relationship different from that of normal 
articular cartilage. 
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Purpose: Monolayer expansion of human articular chondrocytes 
(HAC) is known to result in progressive dedifferentiation and loss 
of stable cartilage formation capacity in vivo. For optimal outcome 
of chondrocyte based repair strategies, HAC capable of ectopic 
cartilage formation may be required. The aim of this study was to 
search for secreted candidate molecules in supernatants of cultured 
HAC predictive of ectopic cartilage formation capacity of cells. 
Methods and Materials: Standardized medium supernatants (n=5) 
of freshly isolated HAC and chondrocytes expanded for 2 (PD2) 
or 6 population doublings (PD6) were screened for 15 distinct 
interleukins, 8 MMPs and 11 miscellaneous soluble factors by a 
multiplexed immunoassay. Cartilage differentiation markers like 
COMP and YKL-40 were determined by ELISA. Corresponding HAC 
were subcutaneously transplanted into SCID-mice and their capacity 
to form stable cartilage was examined histologically 4 weeks later. 
Results: While freshly isolated chondrocytes generated stable 
ectopic cartilage positive for collagen type II, none of the PD6 
transplants formed cartilaginous matrix. Loss of ectopic stable 
cartilage formation capacity between PD0 and PD6 correlated with 
a drop of MMP3 secretion to D10% of initial levels, while changes 
for other investigated molecules were not predictive. Chondrocytes 
from donors with low MMP3 levels (<10%) at PD2 failed to regenerate 
ectopic cartilage at PD2. 
Conclusions: Loss of stable ectopic cartilage formation capacity in the 
course of HAC dedifferentiation can be predicted by determination 
of relative MMP3 levels demonstrating that standardized culture 
supernatants can be used for quality control of chondrocytes 
dedicated for cell therapeutic approaches. 
